Join to View Full Profile
10630 Little Patuxent PkwySte 209Columbia, MD 21044
Phone+1 410-740-8066
Fax+1 410-740-8068
Are you Dr. Mathis?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Mitchell Mathis Jr., MD is a psychiatrist in Columbia, Maryland. He is currently licensed to practice medicine in Maryland.
Education & Training
National Capital ConsortiumResidency, Psychiatry/Family Medicine, 1997 - 2001
University of California Davis HealthResidency, Family Medicine, 1994 - 1997
Uniformed Services University of the Health Sciences F. Edward Hebert School of MedicineClass of 1994
Certifications & Licensure
MD State Medical License 1997 - 2025
National Board of Physicians and Surgeons Family Medicine- National Board of Physicians and Surgeons Psychiatry
Publications & Presentations
PubMed
- 1 citationsShortened Positive and Negative Symptom Scale as an Alternate Clinical Endpoint for Acute Schizophrenia Trials: Analysis from the US Food & Drug Administration.Mathangi Gopalakrishnan, Tiffany Farchione, Mitchell Mathis, Hao Zhu, Mehul Mehta
Psychiatric Research and Clinical Practice. 2021-01-01 - 13 citationsAssociation of End Point Definition and Randomized Clinical Trial Duration in Clinical Trials of Schizophrenia Medications.Islam R. Younis, Mathangi Gopalakrishnan, Mitchell V. Mathis, Mehul Mehta, Ramana S. Uppoor
JAMA Psychiatry. 2020-10-01 - 19 citationsThe Trend of Increasing Placebo Response and Decreasing Treatment Effect in Schizophrenia Trials Continues: An Update From the US Food and Drug AdministrationMathangi Gopalakrishnan, Hao Zhu, Tiffany Farchione, Mitchell V. Mathis, Mehul Mehta
The Journal of Clinical Psychiatry. 2020-03-03
Press Mentions
The Latest “Breakthrough Therapy”: Expensive New Drugs for Tardive DyskinesiaNovember 15th, 2020
Allergan Announces Positive Phase 3 ACHIEVE II Trial Results for Ubrogepant Published in the Journal of the American Medical AssociationNovember 23rd, 2019
Acadia Pharmaceuticals: This Is Not a Pharmaceuticals CompanyJuly 9th, 2018- Join now to see all
